Charles Schwab
NRXP icon

Charles Schwab’s NRX Pharmaceuticals NRXP Stock Holding History

Charles Schwab’s Portfolio NRXP Stock Details NRXP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-4,373
Closed -$20.6K – 3662
2024
Q1 		$20.6K Hold
4,373
– – ﹤0.01% 3435
2023
Q4 		$20.1K Hold
4,373
– – ﹤0.01% 3486
2023
Q3 		$11.4K Hold
4,373
– – ﹤0.01% 3557
2023
Q2 		$21.1K Hold
4,373
– – ﹤0.01% 3553
2023
Q1 		$28.8K Hold
4,373
– – ﹤0.01% 3457
2022
Q4 		$48.5K Buy
+4,373
New +$44K ﹤0.01% 3366
2022
Q2 		– Sell
-1,200
Closed -$30K – 3613
2022
Q1 		$30K Hold
1,200
– – ﹤0.01% 3569
2021
Q4 		$58K Buy
+1,200
New +$86.6K ﹤0.01% 3499

Other funds holding NRXP

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AI
AdvisorShares Investments Bethesda, Maryland $549M AUM 32.58% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
OWMIAS
One Wealth Management Investment & Advisory Services Miami Beach, Florida $95.3M AUM 25.31% 1-Year Est. Return
NPT
National Philanthropic Trust Jenkintown, Pennsylvania $9.38B AUM 33.37% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Charles Schwab's NRXP Position: Q2 2024 in Review

Charles Schwab sold out of NRX Pharmaceuticals (NRXP) in Q2 2024, closing a stake of 4,373 shares — an estimated $20.6K sold.

Charles Schwab first reported a position in NRXP in Q4 2021 and held it in 8 quarters. The position peaked at $58K in Q4 2021. 19 funds tracked by Wall St. Rank hold NRXP as of Q2 2024.

  • Charles Schwab reported no remaining NRX Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • Charles Schwab sold 4,373 NRX Pharmaceuticals shares in Q2 2024, an estimated $20.6K.
  • Charles Schwab first reported a position in NRX Pharmaceuticals in Q4 2021 and held it in 8 quarters.
  • Charles Schwab's NRX Pharmaceuticals position peaked at $58K in Q4 2021.
  • 19 funds tracked by Wall St. Rank held NRX Pharmaceuticals as of Q2 2024.

Based on Charles Schwab's 13F filing for Q2 2024, filed 12 Aug 2024.